Building treatments for rare and underserved diseases.
Rarivia Therapeutics is a Swiss biopharmaceutical company developing a focused portfolio of programs for serious conditions where patients have few or no disease-modifying options.
A small portfolio. High unmet need.
We work on a select group of rare and neglected diseases — areas large enough to matter to patients, yet too often overlooked. Each program is chosen for a clear biological rationale and a credible path to the clinic.
Our work is early and deliberately quiet. Further detail will follow as programs mature.
Rare neurological disorders
Programs targeting nerve injury and degeneration where no disease-modifying therapy exists today.
Underserved indications
Conditions with sizeable patient populations but limited commercial attention and no approved standard of care.
Selected early programs
Additional research-stage projects held in confidence while we generate the data that matters.
Pragmatic science, disciplined development.
We favour approaches with a strong mechanistic basis and a realistic route to patients — combining established pharmacology, modern human-cell models, and thoughtful development design.
Get in touch.
For partnering, scientific, or general enquiries, contact details will be available here shortly.